Sessions Donald G, Lenox Jason, Spector Gershon J, Newland Donald, Simpson Joseph, Haughey Bruce H, Chao K S Clifford
Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Laryngoscope. 2002 Jul;112(7 Pt 1):1281-8. doi: 10.1097/00005537-200207000-00026.
The best therapeutic approach for the treatment of T3N0M0 (stage III) glottic carcinoma is controversial.
A retrospective study of Tumor Research Project data were performed using patients with T3N0M0 glottic squamous cell carcinoma treated with curative intent by seven different treatment modalities from January 1950 to December 1996 at Washington University School of Medicine/Barnes-Jewish Hospital.
Two hundred patients with T3N0M0 glottic carcinoma were treated using seven modalities: total laryngectomy (TL, n = 30), TL with neck dissection (TL/ND, n = 40), conservation surgery alone (CS, n = 22), radiation therapy alone (RT, n = 29), TL combined with RT (TL/RT, n = 31), TL and ND combined with RT (TL/ND/RT, n = 36), and CS combined with RT (CS/RT, n = 12). The overall 5-year observed survival rate (OS) was 54% and the 5-year disease-specific survival rate (DSS) was 67%. The 5-year DSS for the individual treatment modalities included TL, 65.4%; TL/ND, 76.5%; CS, 71.4%; RT, 56.5%, TL/RT, 51.9%; TL/ND/RT, 71.4%; and CS/RT, 80%. There was no significant difference in DSS for any individual treatment modality (P =.375). The overall local and regional control rate was 74% (148 of 200). The overall recurrence rate was 37.5% with recurrence at the primary site and in the neck of 19.5% and 11%, respectively. Recurrence was not related to treatment modality. The 5-year DSS after treatment of recurrent cancer (salvage rate) was 35.8%. The incidence of distant metastasis was 11% and for second primary cancers it was 19.5%. There was no statistically significant difference in survival between necks initially treated (72%, 5-y DSS) versus necks observed and later treated if necessary (70%, 5-y DSS) (P =.797).
The seven treatment modalities had statistically similar recurrence, complication, and survival rates. Patients with clear surgical margins have a significant survival advantage compared with patients with close and involved margins. Because postoperative radiation therapy in patients with positive margins did not improve survival, formal re-resection of the site of the positive margin should be considered. In patients whose N0 neck was not treated electively, close follow-up observation with meticulous examinations combined with appropriate treatment for subsequent neck disease resulted in a similar survival rate compared with those patients whose N0 necks were treated initially. Six-year minimum follow-up is recommended for early identification of primary and neck recurrence and for discovering expected second primary cancers. Patients treated with RT and CS had statistically similar rates of survival, maintenance of voice, and acquired permanent tracheal stoma. CS is a valid alternative to RT in treating highly selected patients with T3N0 glottic carcinoma.
T3N0M0(III期)声门癌的最佳治疗方法存在争议。
对肿瘤研究项目数据进行回顾性研究,研究对象为1950年1月至1996年12月在华盛顿大学医学院/巴恩斯-犹太医院接受七种不同治疗方式、以治愈为目的的T3N0M0声门鳞状细胞癌患者。
200例T3N0M0声门癌患者接受了七种治疗方式:全喉切除术(TL,n = 30)、全喉切除术加颈部清扫术(TL/ND,n = 40)、单纯保留手术(CS,n = 22)、单纯放射治疗(RT,n = 29)、全喉切除术联合放射治疗(TL/RT,n = 31)、全喉切除术和颈部清扫术联合放射治疗(TL/ND/RT,n = 36)、保留手术联合放射治疗(CS/RT,n = 12)。总体5年观察生存率(OS)为54%,5年疾病特异性生存率(DSS)为67%。各治疗方式的5年DSS分别为:TL,65.4%;TL/ND,76.5%;CS,71.4%;RT,56.5%;TL/RT,51.9%;TL/ND/RT,71.4%;CS/RT,80%。各治疗方式的DSS无显著差异(P = 0.375)。总体局部和区域控制率为74%(200例中的148例)。总体复发率为37.5%,原发部位和颈部复发率分别为19.5%和11%。复发与治疗方式无关。复发性癌症治疗后的5年DSS(挽救率)为35.8%。远处转移发生率为11%,第二原发癌发生率为19.5%。初始治疗的颈部与观察等待并在必要时后续治疗的颈部之间的生存率无统计学显著差异(72%,5年DSS对70%,5年DSS)(P = 0.797)。
七种治疗方式在复发、并发症和生存率方面在统计学上相似。手术切缘清晰的患者与切缘接近和受累的患者相比具有显著的生存优势。由于切缘阳性患者的术后放射治疗并未改善生存率,应考虑对阳性切缘部位进行正式再次切除。在未选择性治疗N0颈部的患者中,密切随访观察并进行细致检查,结合对后续颈部疾病的适当治疗,其生存率与初始治疗N0颈部的患者相似。建议进行至少6年的随访,以早期发现原发灶和颈部复发,并发现预期的第二原发癌。接受放射治疗和保留手术的患者在生存率、声音保留和获得永久性气管造口方面在统计学上相似。在治疗高度选择的T3N0声门癌患者时,保留手术是放射治疗的有效替代方法。